One year data on Evoque transcatheter tricuspid valve replacement.- Edwards Lifesciences.

The data were presented during the late-breaking trials session at PCR London Valves 2022.

Patients enrolled in the TRISCEND study had symptomatic moderate or greater functional or degenerative tricuspid regurgitation (TR), despite optimal medical therapy. The TRISCEND study enrolled 176 patients, representing the largest dataset among transcatheter tricuspid valve replacement therapies. Following positive 30-day and 6-month results, the one-year outcomes demonstrated: i. High survival of 90.1% and high freedom from heart failure hospitalization at 88.4%; ii. Significant and sustained TR reduction, with 97.6% of patients with mild or trace TR (n=84); iii. Significantly improved functional and quality-of-life outcomes, with 93% of patients in NYHA Class I or II compared to 26% at baseline (n=89) and a 26-point increase in KCCQ score over baseline (n=102).

"Tricuspid regurgitation is prevalent, undertreated and has a significant impact on patients' quality of life. With most TR patients at high risk for surgery, there is a great need for an approved transcatheter valve replacement treatment option," said Prof. Didier Tchetche, MD, Clinique Pasteur, Toulouse, France and TRISCEND study co-primary investigator. "The one-year results for patients who received the Evoque tricuspid valve replacement as part of the TRISCEND study provide important support for our confidence in this therapy as an option for patients who suffer from tricuspid regurgitation.".

The Evoque valve replacement system is an investigational device and is not available for sale in any country. The TRISCEND II randomized pivotal trial is currently underway. The Evoque system is one of several transcatheter replacement or repair therapies in development by Edwards as part of the company's commitment to transform the treatment of patients with mitral and tricuspid valve disease, supported by robust contemporary clinical evidence.